BofA analyst Jason Gerberry downgraded Viatris to Underperform from Neutral with a price target of $9, down from $13. The firm sees a lack of company catalysts and notes that Viatris shares realized no upside on recent OTC divestitures. The firm, which calls Viatris a “transition story” as it looks to redeploy $2.55B in proceeds for specialty brands and away from generics, says it could be tough to secure quality assets in its target therapeutic areas of dermatology, gastrointestinal and ophthalmic.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTRS:
- Viatris price target lowered to $11 from $12 at UBS
- Mylan challenge of two GLP-1 patents denied, Bloomberg says
- Early notable gainers among liquid option names on October 2nd
- Viatris agrees to divest Women’s Healthcare unit, API unit in India
- Viatris receives offer for divestiture of substantially all of OTC business